Galecto hires new Chief Medical Officer. Lindmark joins from the eTheRNA immunotherapies, which is a Belgian mRNA immunotherapy company. He has also had an extensive and successful career in the pharmaceutical industry. Lindmark was the Global Vice President of Clinical Development for the Respiratory and Inflammation franchises at AstraZeneca. It was here he led the development of Symbicort along with many other gastro-intestinal products. From 2010, he headed Research and Development at Almirall before joining ASLAN pharmaceuticals in Singapore where he focused on atopic skin and lung diseases as well as cancer.